Effect of Human Blood Mononuclear Cell Populations in Antibody Dependent Cellular Cytotoxicity (ADCC) Using Two Murine (CO 17-1A and Br55-2) and One Chimeric (17-1A) Monoclonal Antibodies Against a Human Colorectal Carcinoma Cell Line (SW948)
- 1 October 1988
- journal article
- research article
- Published by Mary Ann Liebert Inc in Hybridoma
- Vol. 7 (5) , 429-440
- https://doi.org/10.1089/hyb.1988.7.429
Abstract
Peripheral blood mononuclear cells (PBMC) from healthy individuals were studied for their lytic capability in ADCC using SW948 (a human colorectal carcinoma cell line) as target cells. Three monoclonal antibodies (MAbs) were used: two mouse MAbs (IgG2A) against the antigenic structures CO 17-1A and BR55-2 respectively and one chimeric MAb 17-1A (IgG1) (mouse-human). Three kinds of effector cells were prepared. PBMC were purified on a Ficoll-Isopaque gradient (FIP cells) (a mixture of lymphocytes and monocytes). To obtain pure monocytes (>90%), PBMC were centrifuged on a Nycodenz gradient (Nycodenz cells). Highly purified lymphocytes (>98%) were obtained by treatment of FIP cells with iron powder and removal of phagocytic cells (PBL cells). Monocytes had the highest lytic capability. FIP cells were less effective than monocytes. PBL cells had the poorest killing activity. In reconstitution experiments addition of increasing amount of monocytes to PBL resulted in an augmented cytotoxicity. The numbers of Leu-M3+ cells, Leu-M5+ cells (monocytes) and CD16+ cells correlated positively to cytotoxicity. Higher concentration of MAb 17-1A was required to reach the same level of cytotoxicity using FIP cells as effector cells as compared to monocytes. MAb BR55-2 induced the same cytotoxic activity as MAb 17-1A. Combination of these two MAbs did not increase the lytic capability. Chimeric MAb 17-1A mediated ADCC in a dose-dependent fashion. The chimeric MAb was consistently more effective than the mouse MAb.This publication has 17 references indexed in Scilit:
- Isolation and Characterization of Autologous Blood Mononuclear Cells Used for Auto-Infusion Together with Monoclonal Antibodies in Tumor TreatmentHybridoma, 1987
- In vitro immunization for production of murine and human monoclonal antibodies: Present statusTrends in Biotechnology, 1986
- Tumors undergoing rejection induced by monoclonal antibodies of the IgG2a isotype contain increased numbers of macrophages activated for a distinctive form of antibody-dependent cytolysis.Proceedings of the National Academy of Sciences, 1984
- Human anti-idiotype antibodies in cancer patients: Is the modulation of the immune response beneficial for the patient?Proceedings of the National Academy of Sciences, 1984
- Human Macrophages Armed with Murine Immunoglobulin G2a Antibodies to Tumors Destroy Human Cancer CellsScience, 1983
- Isolation of Human Blood Monocytes with Nycodenz, a New Non‐Ionic lodinated Gradient MediumScandinavian Journal of Immunology, 1983
- Blood and Lymph Node T‐Lymphocyte Subsets in Non‐Hodgkin LymphomasScandinavian Journal of Haematology, 1983
- Monoclonal antibodies in cell‐mediated cytotoxicity against human melanoma and colorectal carcinomaEuropean Journal of Immunology, 1979
- Study of antibodies against human melanoma produced by somatic cell hybrids.Proceedings of the National Academy of Sciences, 1978
- Continuous cultures of fused cells secreting antibody of predefined specificityNature, 1975